Immunic, Inc. filed 8 current reports with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-09-11. Between them they name 7 people, with 5 appointments and 3 departures. Each change below is quoted from the filing and linked to it.
Every change, newest first
Departing: Duane Nash, Director
On September 10, 2026, Dr. Duane Nash resigned as a member of the Board of Directors (the "Board") of Immunic, Inc., a Delaware corporation (the "Company").
Appointed: Elena Ridloff, Director
On August 6, 2026, the board of directors (the "Board") of the Company appointed Elena Ridloff as a member of the Board, effective immediately.
Departing: Tamar Howson, Director
On June 29, 2026, Tamar Howson resigned as a member of the Compensation Committee of the Board of Directors (the " Board ") of Immunic, Inc., a Delaware corporation (the " Company "), and as a member of the Board, as Ms. Howson transitions into retirement.
Appointed: Erik Lundgren, Chief Executive Officer
On May 22, 2026 (the "Effective Date"), Immunic, Inc. (the "Company") appointed Erik Lundgren, as Chief Executive Officer of the Company, with his start of employment beginning on June 1, 2026.
Appointed: Michael W. Bonney, Chair of the Board
Appointment of Michael W. Bonney as Chair of the Board On May 16, 2026 (the "Effective Date"), the board of directors (the "Board") of Immunic, Inc., a Delaware corporation (the "Company") appointed Michael W. Bonney as Chair of the Board, effective immediately.
Appointed: Michael A. Panzara, Chief Medical Officer, effective 2026-04-24
Appointment of Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer Effective April 24, 2026 (the "Effective Date"), Immunic, Inc. (the "Company") appointed Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer of the Company, effective immediately.
Departing: Andreas Muehler, Chief Medical Officer
Resignation of Andreas Muehler, M.D., M.B.A. On April 27, 2026, Andreas Muehler, M.D., M.B.A., resigned as the Chief Medical Officer of the Company.
Appointed: Andreas Muehler
Dr. Muehler will serve as Senior Medical Officer through the Separation Date.
Reported
The Agreement was entered into in connection with the Company's commencement of a search for a new Chief Executive Officer, and Mr. Vitt's potential transition to a "C-Suite" role that is focused on strengthening the Company's scientific strategy and driving portfolio advancement after a new Chief Executive Officer is hired.
Reported
On March 31, 2026, Immunic, Inc., a Delaware corporation (the "Company"), announced the appointment of Jon Congleton as a member of the board of directors (the "Board") of the Company, effective as of March 27, 2026.
Find people with the same kind of experience as the Director at Immunic, Inc., with the record behind each one.
Find candidates like Director at Immunic, Inc.New leaders review vendors and budgets in their first months. Get an alert the next time Immunic, Inc. is in the news or changes leadership.
Get an alert when Immunic, Inc. changes leadershipTools for this story
Each opens in a new tab, filled in for Immunic, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.